{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05798611",
            "orgStudyIdInfo": {
                "id": "ART0380C004"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-504153-12",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Artios Pharma Ltd",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of ART0380 in Patients With Biologically Selected Solid Tumors",
            "officialTitle": "A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients With Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)",
            "acronym": "ARTIST",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-patients-with-biologically-selected-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-23",
            "studyFirstSubmitQcDate": "2023-03-23",
            "studyFirstPostDateStruct": {
                "date": "2023-04-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Artios Pharma Ltd",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).",
            "detailedDescription": "ART0380 is being developed as an oral anti-cancer agent for the treatment of patients with cancers that have defects in deoxyribonucleic acid (DNA) repair.\n\nThe study will recruit selected patients with advanced or metastatic solid tumors, specifically:\n\n* Patients with persistent or recurrent endometrial cancer (EC)\n* Patients with advanced or metastatic solid tumors of any histology\n\nAbove patients will be randomized in a 1:1 ratio to one of two dose regimens of ART0380.\n\nSafety will be evaluated on a quarterly basis, at a minimum. Patients may continue to receive ART0380 as long as they are continuing to derive benefit from treatment or until disease progression, withdrawal of consent, or until they experience unacceptable drug-related toxicity."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Recurrent Endometrial Cancer",
                "Metastatic Cancer"
            ],
            "keywords": [
                "Solid Tumors",
                "Monotherapy",
                "Cancer cell",
                "Oral anti-cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1 [ART0380 monotherapy (endometrial cancer patients)]",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with persistent or recurrent endometrial cancer (EC) will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ART0380"
                    ]
                },
                {
                    "label": "Arm 2 [ART0380 monotherapy (solid tumors patients)]",
                    "type": "EXPERIMENTAL",
                    "description": "Patients with advanced or metastatic solid tumors will receive ART0380 monotherapy on either a continuous daily dose or on an intermittent schedule for a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ART0380"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ART0380",
                    "description": "Randomized patients will orally receive ART0380.",
                    "armGroupLabels": [
                        "Arm 1 [ART0380 monotherapy (endometrial cancer patients)]",
                        "Arm 2 [ART0380 monotherapy (solid tumors patients)]"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "Objective Response Rate (ORR) is defined as the proportion of patients with a complete response (CR) or partial response (PR) to treatment according to Response evaluation criteria in solid tumors (RECIST v1.1).",
                    "timeFrame": "Until disease progression (Every 6 weeks from randomization Upto 2 Years)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of patients with adverse events",
                    "description": "To assess the safety and tolerability of ART0380 in patients with solid tumors.",
                    "timeFrame": "From Cycle 1 (each Cycle is 21-day) Day 1 until 30-day follow-up visit (Upto 2 Years)"
                },
                {
                    "measure": "Progression free survival (PFS)",
                    "description": "The PFS is defined as the time from randomization until the earliest objective disease progression defined by RECIST v1.1 or Prostate Cancer Working Group 3 (PCWG-3) (for patients with prostate cancer in Arm 2) or death by any cause in the absence of progression, regardless of whether the patient withdraws from study medication or receives another anti-cancer therapy prior to progression.",
                    "timeFrame": "Screening (\u226428 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)"
                },
                {
                    "measure": "Best overall response (BOR)",
                    "description": "The best overall response is the best response (complete response, and partial response) recorded from the date of randomization for each patient until the progression or censoring date in the absence of progression.",
                    "timeFrame": "Screening (\u226428 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)"
                },
                {
                    "measure": "Disease control rate (DCR)",
                    "description": "To further explore the efficacy of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms.",
                    "timeFrame": "Screening (\u226428 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)"
                },
                {
                    "measure": "Duration of response (DOR)",
                    "description": "The DOR will be defined for patients with a BOR of CR/PR, as the time from the date of first documented response until date of documented progression (by RECIST v1.1) or death in the absence of disease progression.",
                    "timeFrame": "Screening (\u226428 days) Until disease progression or death (Every 6 weeks from randomization Upto 2 Years)"
                },
                {
                    "measure": "Change in tumor size",
                    "description": "The best percentage change in tumor size from baseline will be determined for each patient, ie, the maximum reduction from baseline or the minimum increase from baseline in the absence of a reduction.",
                    "timeFrame": "Screening (\u226428 days) Until disease progression (Every 6 weeks from randomization Upto 2 Years)"
                },
                {
                    "measure": "Overall survival (OS)",
                    "description": "The OS is defined as the time from the randomization until death due to any cause.",
                    "timeFrame": "Screening (\u226428 days) Until overall survival follow-up (Every 12 weeks until data cut-off)"
                },
                {
                    "measure": "Maximum plasma concentration (Cmax)",
                    "description": "To determine the Cmax of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms.",
                    "timeFrame": "Pre-dose Cycle 1 day 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)"
                },
                {
                    "measure": "Half life (t1/2)",
                    "description": "To determine the t1/2 of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms.",
                    "timeFrame": "Pre-dose Cycle 1 days 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)"
                },
                {
                    "measure": "Area under the plasma concentration-time curve from zero to infinity (AUC0-inf)",
                    "description": "To determine the AUC0-inf of ART0380 following single oral dosing of ART0380 in patients with solid tumors enrolled in each of the biologically defined arms.",
                    "timeFrame": "Pre-dose Cycle 1 days 1, 2, 15, 16, 17, 18, Cycle 2 day 1, Cycle 3 day 1 Upto 2 Years (Each Cycle is 21-days)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who have discontinued all previous treatments for cancer for at least 21 days or 5 half-lives (not including palliative radiotherapy at focal sites), whichever is shorter. Palliative radiotherapy must have completed 1 week prior to start of study treatment.\n* Resolution of all toxicities of prior therapy or surgical procedures to baseline or Grade 1 (except for hypothyroidism requiring medication, neuropathy, and alopecia, which must have resolved to Grade \u22642).\n* Have adequate organ function.\n* Patients of childbearing potential and patients with partners of childbearing potential are required to use highly effective contraception.\n* Have an estimated life expectancy of \u226512 weeks, in the judgment of the investigator.\n* Performance status of 0-1 on the Eastern Cooperative Oncology Group scale.\n* Have a non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available.\n\nInclusion Criteria specific to each Arm\n\nInclusion Criteria for Arm 1 \\[ART0380 monotherapy (endometrial cancer patients)\\]\n\n* Persistent or recurrent EC with biological selection.\n* Patients should have received taxane/platinum chemotherapy unless contraindicated.\n* Measurable disease.\n\nInclusion Criteria for Arm 2 \\[ART0380 monotherapy (solid tumors patients)\\]\n\n* Advanced or metastatic solid cancers of any histology with biological selection.\n* If a Programmed cell death protein-1 /Programmed death-ligand-1 inhibitor (e.g., pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study.\n* Radiologically evaluable disease.\n\nExclusion Criteria:\n\n* Patients who are pregnant.\n* Prior treatment with an inhibitor of ATR, WEE1, checkpoint kinase 1 or PKMYT1.\n* Have a serious concomitant systemic disorder that would compromise the patient's ability to adhere to the protocol.\n* Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression.\n* Have any major gastrointestinal issues that could impact absorption of ART0380.\n* Have a history of allergy or hypersensitivity to study drug components.\n* Have a significant bleeding disorder or vasculitis or had a Grade \u22653 bleeding episode within 12 weeks prior to enrollment.\n* Patients receiving potent inhibitors and inducers of CYP3A4 or CYP3A4 substrates which have a narrow therapeutic range or CYP3A4 sensitive substrates within 2 weeks before the first dose of study treatment will be excluded.\n* Patients receiving the following within 2 weeks of the first dose will be excluded from study treatment.\n\n  1. P-glycoprotein or breast cancer resistance protein (BCRP) inhibitors\n  2. Statins\n* Patients who plan to father a child while in the study or within 16 weeks (5 months in France) after the last administration of study treatment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Artios Pharma",
                    "role": "CONTACT",
                    "phone": "+44 (0)1223 867 900",
                    "email": "info@artios.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of California Los Angeles (UCLA)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095-1781",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "The University of Chicago",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637-1447",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Dana Farber Cancer Center",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Northwell Health R.J. Zuckerberg Cancer Center",
                    "status": "RECRUITING",
                    "city": "Lake Success",
                    "state": "New York",
                    "zip": "11042",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.77066,
                        "lon": -73.71763
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center (MSKCC) - Memorial Hospital - Oncology",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Oklahoma/Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Western Pennsylvania Hospital",
                    "status": "RECRUITING",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15224",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                },
                {
                    "facility": "Women and Infants Hospital",
                    "status": "RECRUITING",
                    "city": "Providence",
                    "state": "Rhode Island",
                    "zip": "02905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.82399,
                        "lon": -71.41283
                    }
                },
                {
                    "facility": "Institut de Canc\u00e9rologie de l'Ouest",
                    "status": "RECRUITING",
                    "city": "Angers",
                    "state": "NAP",
                    "zip": "49055",
                    "country": "France",
                    "geoPoint": {
                        "lat": 47.46667,
                        "lon": -0.55
                    }
                },
                {
                    "facility": "Centre Francois Baclesse - Service d'Oncologie m\u00e9dicale",
                    "status": "RECRUITING",
                    "city": "Caen",
                    "state": "NAP",
                    "zip": "14076",
                    "country": "France",
                    "geoPoint": {
                        "lat": 49.18585,
                        "lon": -0.35912
                    }
                },
                {
                    "facility": "Hopital Cochin Saint Vincent De Paul",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "state": "NAP",
                    "zip": "75014",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Hopital Lyon Sud",
                    "status": "RECRUITING",
                    "city": "Pierre-Benite",
                    "state": "NAP",
                    "zip": "69310",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.7009,
                        "lon": 4.82511
                    }
                },
                {
                    "facility": "Centre Hospitalier Universitaire De Poitiers",
                    "status": "RECRUITING",
                    "city": "Poitiers",
                    "state": "NAP",
                    "zip": "86000",
                    "country": "France",
                    "geoPoint": {
                        "lat": 46.58333,
                        "lon": 0.33333
                    }
                },
                {
                    "facility": "Hospital Universitario De Ja\u00e9n",
                    "status": "RECRUITING",
                    "city": "Ja\u00e9n",
                    "state": "Andaluc\u00eda",
                    "zip": "23007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.76922,
                        "lon": -3.79028
                    }
                },
                {
                    "facility": "Fundaci\u00f3n Instituto Valenciano De Oncolog\u00eda",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46009",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016889",
                    "term": "Endometrial Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000014594",
                    "term": "Uterine Neoplasms"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000014591",
                    "term": "Uterine Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M19235",
                    "name": "Endometrial Neoplasms",
                    "asFound": "Endometrial Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17342",
                    "name": "Uterine Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17339",
                    "name": "Uterine Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        }
    },
    "hasResults": false
}